I don't understand..someone please explain:
Roche paid $65 mill up front and up to $530 in milestones for exclusive rights to market Octreolin.....for Acromegaly
Atl1103 is more potent,cheaper.and safer than the major treatment drugs at present
The estimated market for Anp is $200 million per annum
And you guys are talking $5 and $10 mill license fees....lol
Atl1102 has not gone to market or interested pharmas because only a month ago they got the OK from the FDA...
Expect the same license fees as above,
Ann: Company Update, page-108
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.015(13.0%) |
Mkt cap ! $117.2M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 13.5¢ | 12.0¢ | $612.7K | 4.843M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 56662 | 13.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 600000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |